Obesity

Allurion Announces Preliminary First Quarter 2024 Results

Retrieved on: 
Tuesday, April 30, 2024
Biotechnology, Managed Care, General Health, Health, Medical Devices, Health Technology, Fitness & Nutrition, Other Health, Obesity, United, Growth, Mobile phone

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024.

Key Points: 
  • Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024.
  • Management expects preliminary unaudited results for the period as follows:
    Revenue in the range of $9.2 million to $9.3 million, reflecting growth of between 12%-13% over the fourth quarter of 2023
    Procedural volume growth, as estimated by new app users, reflecting 22% growth over the fourth quarter of 2023
    Cash burn in the range of $8 million to $9 million, down from $22 million in the fourth quarter of 2023, and in line with targeted cash burn of approximately $30 million for the year
    “We are encouraged by our growth in the first quarter in both revenue and procedural volume, while slowing our cash burn rate,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer.
  • “We believe awareness and demand for the Allurion Program will continue to grow in subsequent quarters, and we expect the business to feed off of recent catalysts, including the launch of the Allurion Virtual Care Suite in the United States and the first reimbursed procedures in the United Kingdom.”
    The Company will host a conference call on Tuesday, May 14, 2024, at 8:30 AM ET to discuss first quarter financial results and provide a business update.

New Campaign Brings to Forefront How Preeclampsia Prevention is Possible for Pregnant Women

Retrieved on: 
Wednesday, May 1, 2024
Women, Biotechnology, Surgery, Health, Baby, Maternity, Hospitals, Consumer, Other Health, Patient, Risk, Pregnancy, Aspirin, MD, Survivor, Disease, Obesity, Exercise, Pre-eclampsia, Cardiovascular disease, FACOG, Birth control

As May marks Preeclampsia Awareness Month , leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, “ Preeclampsia Prevention is Possible .” The campaign elevates awareness of a major paradigm shift underway focused on the prevention of the disease, encouraging the use of evidence-based strategies so pregnant patients and providers can actively work together to create the healthiest pregnancy possible.

Key Points: 
  • As May marks Preeclampsia Awareness Month , leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, “ Preeclampsia Prevention is Possible .” The campaign elevates awareness of a major paradigm shift underway focused on the prevention of the disease, encouraging the use of evidence-based strategies so pregnant patients and providers can actively work together to create the healthiest pregnancy possible.
  • “Preeclampsia is often viewed as a complication with limited ability to intervene early and lower the risk of developing the condition,” said Eleni Tsigas, CEO of the Preeclampsia Foundation and preeclampsia survivor.
  • “However, all year long, and especially during Preeclampsia Awareness Month, we’re amplifying the message that we are in an era where we can better predict, prevent, and prevail over the adverse outcomes caused by preeclampsia.
  • “With objective, personalized data, pregnant patients can finally know their risk, create a plan and work with their care team to take every possible measure to prevent preeclampsia.”
    Patients and providers can access the educational toolkit at PreeclampsiaPrevention.com .

Real Chemistry Introduces Iris: An Insights-as-a-Service Platform Delivering Timely Insights on the Obesity Market and the Growing Influence of GLP-1 Therapies

Retrieved on: 
Tuesday, April 30, 2024
Software, General Health, Professional Services, Search Engine Optimization, Search Engine Marketing, Technology, Artificial Intelligence, Marketing, Advertising, Communications, Other Technology, Health, Consulting, Real, Ecosystem, Policy, AI, IRIS, Obesity, Pressure, Patient, A New Era, Physician, Multimedia, Beauty, Real Chemistry, Organization, Nursing

Fueled by the analysis of billions of data points using Real Chemistry’s proprietary AI, analytics and insights tools, IRIS offers a live dashboard and timely market reports.

Key Points: 
  • Fueled by the analysis of billions of data points using Real Chemistry’s proprietary AI, analytics and insights tools, IRIS offers a live dashboard and timely market reports.
  • View the full release here: https://www.businesswire.com/news/home/20240430140657/en/
    The IRIS platform offers a multi-dimensional and aggregated view across market performance, market access dynamics, the policy landscape, consumer behaviors and clinical milestones.
  • “No other therapeutic category has the emotional, psychological, physical, clinical, cultural and economic impact that treating obesity brings.
  • Growing consumer-led, online communities are joining forces to navigate and advise others on managing market impacts, such as shortages and access.

Fresh Del Monte and University of Granada Announce Expanded Partnership to Research the Effectiveness of Bioactive Compounds of Fruit Residues in Medical and Non-Medical Uses

Retrieved on: 
Monday, April 29, 2024
Chemicals, Plastics, Retail, Manufacturing, University, Education, General Health, Supply Chain Management, Agriculture, Natural Resources, Supermarket, Specialty, Science, Food, Beverage, Packaging, Research, Health, Transfer, Vegetable, Mineral, Fresh Del Monte Produce, Diabetes, Biomedical Research, Partnership, Vitamin, Obesity, Food industry, Environment, Multimedia, Beauty, Antioxidant, UGR, Fruit, FDP, University of Granada

The partnership comes after more than a year of initial research that looked into the effectiveness of bioactive compounds from certain fruits within Fresh Del Monte’s portfolio yielded promising results.

Key Points: 
  • The partnership comes after more than a year of initial research that looked into the effectiveness of bioactive compounds from certain fruits within Fresh Del Monte’s portfolio yielded promising results.
  • “This collaboration with a company like Fresh Del Monte highlights how the concept of circular economy is deeply rooted in the food industry.
  • By joining forces, Fresh Del Monte and UGR's Research Transfer Office (OTRI) aim to enhance ongoing research and development initiatives focused on utilizing fruit residue to create valuable products that promote healthy lifestyles.
  • The ongoing partnership is scheduled to span 18 months, with key milestones delineated at various stages of the program.

Supergut, the Leader in GLP-1 Functional Foods, Accelerates Its Unprecedented Retail Expansion With Newest Partner, GNC

Retrieved on: 
Monday, April 29, 2024
General Health, Food, Beverage, Health, Retail, Fitness & Nutrition, Brain, Malnutrition, Digestion, Walmart, GNC, Bristol Farms, Nausea, Overweight, Diabetes, Insurance, Weight loss, Partnership, GLP-1, Atrophy, Prescription, Obesity, Food industry, Exercise, Science, Vomiting, Starch, Diarrhea, Metabolism, Constipation, Multimedia, Cardiovascular disease, Prediabetes, Immunity, Sleep, Injection, Dietary supplement

The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.

Key Points: 
  • The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.
  • In addition to this retail explosion, Supergut remains available on Supergut.com and Amazon .
  • “We’re excited to partner with GNC, which shares our values of scientific validation and customer education.
  • Approximately five million Americans take these drugs now, and up to 70 million Americans may use a GLP-1 by 2028 .

Recruiting Participants for the 365mc Global Social Contribution Campaign ‘Global Better Me Season 2’

Retrieved on: 
Tuesday, April 30, 2024
Other Health, Consumer, Other Education, Destinations, Hospitals, Travel, Fitness & Nutrition, Cosmetics, Education, Retail, Surgery, Women, Health, Obesity, Patient, Record, Diet, Multimedia, Beauty, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240429213655/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240429213655/en/
    Before Global Better Me (Photo: 365mc)
    The specialized obesity treatment clinic and liposuction medical institution, 365mc , announced on the 8th that they are recruiting participants for the second installment of the ‘Global Better Me’ Season 2 campaign, targeting foreign patients with obesity worldwide.
  • The global social contribution obesity treatment campaign 'Global Better Me' started last year with the intent to help those suffering find a better 'me' and discover greater beauty.
  • 365mc supports individuals who have been worn down by the negative perceptions of society so that they can discover a better version of themselves.
  • With the success of the first campaign, 365mc is now looking for the season 2, second heroes to fulfill their 'Korean Dream.'

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Retrieved on: 
Tuesday, April 30, 2024
Contract research organization, American Diabetes Association, GAN, Part, Congress, EASL, Gubra, OXM, Weight loss, GCGR, GLP1R, GPR119, Obesity, SAD, Glucagon-like peptide-1 receptor, MASH, Pharmaceutical industry

"We have completed enrollment for Part 1 of our Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Key Points: 
  • "We have completed enrollment for Part 1 of our Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
  • DA-1726 has consistently shown, in our preclinical data, to sustain weight loss in diet-induced obese models by decreasing food consumption and boosting energy expenditure.
  • Both programs are progressing well, and we have been able to significantly accelerate the clinical timelines for DA-1726.
  • A member of the Dong-A ST Research Center will present pre-clinical data on DA-1726 in a poster presentation at this scientific session in Orlando, FL.

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

Retrieved on: 
Wednesday, April 10, 2024
University, Ipsen, Obesity, Novartis, IPO, Therapy, Pfizer, CML, Head, Biology, Biogen, Sangamo Therapeutics, Growth, Pharmaceutical industry

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.

Key Points: 
  • FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
  • “We are excited to welcome Melita to the Terns leadership team at a critical stage of growth at the company,” said Amy Burroughs, chief executive officer of Terns.
  • Most recently, she served as chief business officer at Structure Therapeutics, where she was responsible for the company’s business strategy, partnering initiatives, commercial planning, corporate branding and communications.
  • Previously, Ms. Jung served as senior vice president and head of business development at Sangamo Therapeutics, a genomic medicines company.

Skye Bioscience Uplists to The Nasdaq Global Market

Retrieved on: 
Wednesday, April 10, 2024
Obesity, CB1, SAN, The Company, OTCQB, Pharmaceutical industry

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global Market® stock exchange ("Nasdaq").

Key Points: 
  • SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global Market® stock exchange ("Nasdaq").
  • The Company's common stock is expected to commence trading on Nasdaq at the market open on Thursday, April 11th, 2024, under the ticker symbol "SKYE".
  • The Company's common stock will no longer trade on the over-the-counter securities market.
  • "This listing to the Nasdaq Global Market is a validation of Skye and its recent performance," said Punit Dhillon, Chief Executive Officer and Chairman.

Oncology Precision Medicine Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2024
Pharmaceutical, Health, Oncology, Molecule, USD, Mortality, Radiation, Volunteering, Administration, Breast cancer, Cancer, Lung cancer, World Health Organization, Hub, Risk, Immunotherapy, Research, Genetic testing, Obesity, Disease, DNA, Therapy, Oncogene, Patient, Gastrointestinal cancer, Bone marrow, MD Anderson Cancer Center, Clinical trial, Medicine, Viral, Type, Interest, Mayo Clinic Cancer Center, Growth, Prevalence, Medical imaging

The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.

Key Points: 
  • The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.
  • Regional Analysis: North America Emerged as the Hub of Oncology Precision Medicine; Europe to be the Fastest Growing Market
    In 2024, North America is anticipated to capture close to 42% market share of the overall oncology precision medicine market.
  • In recent years, demand for oncology precision medicine has witnessed a tremendous increase in North America.
  • The oncology precision medicine market report presents an in-depth analysis of various precision medicine oncology companies in this domain, across different segments, as defined below: